



A SURESH G KARE Enterprise

## INDOCO REMEDIES LIMITED

Regd. Office: Indoco House, 166, C.S.T. Road, Santacruz (E), Mumbai 400 098

### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2008

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended 30.09.2008 (Unaudited)	Quarter ended 30.09.2007 (Unaudited)	Six Months ended 30.09.2008 (Unaudited)	Six Months ended 30.09.2007 (Unaudited)	Year ended 31.03.2008 (Nine Months)* (Audited)
1	<b>(a) Sales and Income from Operations</b>	<b>7,968</b>	8,776	<b>19,058</b>	19,384	<b>27,189</b>
	Less : Excise Duty	106	333	247	909	921
	<b>Net Sales and Income from Operations</b>	<b>7,862</b>	8,443	<b>18,811</b>	18,475	<b>26,268</b>
	<b>(b) Other Operating income</b>	<b>72</b>	58	<b>136</b>	133	<b>225</b>
	<b>Total</b>	<b>7,934</b>	8,501	<b>18,947</b>	18,608	<b>26,493</b>
2	<b>Total Expenditure :</b>					
	(a) (Increase)/Decrease in Stock in trade and work in progress	(61)	(135)	(416)	165	(295)
	(b) Consumption of Raw Materials	2,752	2,852	6,506	5,787	8,819
	(c) Purchase of Traded Goods	673	824	1,803	1,864	2,749
	(d) Employees cost	1,215	981	2,338	1,903	3,227
	(e) Depreciation	252	251	536	507	778
	(f) Research & Development Expenses	229	195	434	352	718
	(g) Other Expenditure	2,471	2,120	4,737	4,138	6,774
	(h) Total	7,531	7,088	15,938	14,716	22,770
3	<b>Profit from Operations before Other Income, Interest and Exceptional Items</b>	<b>403</b>	1,413	<b>3,009</b>	3,892	<b>3,723</b>
4	Other Income	26	15	48	16	25
5	<b>Profit before Interest and Exceptional Items</b>	<b>429</b>	1,428	<b>3,057</b>	3,908	<b>3,748</b>
6	Interest	146	120	282	281	361
7	<b>Profit after Interest but before Exceptional Items</b>	<b>283</b>	1,308	<b>2,775</b>	3,627	<b>3,387</b>
8	Exceptional Items	-	-	-	-	-
9	<b>Profit from Ordinary Activities before tax</b>	<b>283</b>	1,308	<b>2,775</b>	3,627	<b>3,387</b>
10	Provision for Tax - Current	30	146	309	338	355
	- Deferred	40	58	78	221	123
	- Fringe Benefit Tax	26	19	51	25	72
	- Prior Year	-	-	(31)	10	-
	- MAT Credit	(30)	-	(309)	(418)	(355)
11	<b>Profit from Ordinary Activities after tax</b>	<b>217</b>	1,085	<b>2,677</b>	3,451	<b>3,192</b>
12	Extraordinary Items	-	-	-	159	182
13	<b>Net Profit for the period</b>	<b>217</b>	1,085	<b>2,677</b>	3,292	<b>3,010</b>
14	Paid up Equity Share Capital (Face value Rs.10/- each)	1,228.67	1228.67	1228.67	1228.67	1,228.67
15	Reserves excluding Revaluation Reserves	-	-	-	-	-
16	<b>Earning Per Share (EPS) - Not Annualised - Rs.</b>					
	(a) Basic and diluted EPS before Extraordinary items	1.77	8.83	21.79	28.09	25.98
	(b) Basic and diluted EPS after Extraordinary items	1.77	8.83	21.79	26.79	24.50
17	Public shareholding					
	- No of Shares	48,48,291	48,84,674	48,48,291	48,84,674	48,82,016
	- % of Shareholding	39.45	41.31	39.45	41.31	39.73

Notes :

- \* In view of the decision to change the accounting year of the company from July-June to April-March, the Financial Year for 2007-08 is for 9 months period from 1st July 2007 to 31st March 2008.
- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- The figures for the previous periods have been regrouped and reclassified, wherever necessary.
- Summary of investor complaints : As on 01.7.2008 : Nil, Received during quarter : 1, Resolved : 1, Pending as on 30.09.2008 : Nil
- The above results have been recommended by the Audit Committee and taken on record at the meeting of Board of Directors held on 31st October 2008 and have been subjected to a Limited Review by the Statutory Auditors of the Company.

By Order of the Board

Suresh G. Kare  
Chairman & Managing Director

Place: Mumbai  
Date : October 31, 2008